ADIM
GBT

Alpha DNA Investment Management’s Global Blood Therapeutics, Inc. GBT Stock Holding History

Alpha DNA Investment Management’s Portfolio GBT Stock Details GBT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-80
Closed -$3K – 729
2021
Q1 		$3K Hold
80
– – ﹤0.01% 540
2020
Q4 		$3K Buy
+80
New +$3.94K ﹤0.01% 435

Other funds holding GBT

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Alpha DNA Investment Management's GBT Position: Q2 2021 in Review

Alpha DNA Investment Management sold out of Global Blood Therapeutics, Inc. (GBT) in Q2 2021, closing a stake of 80 shares — an estimated $3K sold.

Alpha DNA Investment Management first reported a position in GBT in Q4 2020 and held it in 2 quarters. The position peaked at $3K in Q1 2021. 191 funds tracked by Wall St. Rank hold GBT as of Q2 2021.

  • Alpha DNA Investment Management reported no remaining Global Blood Therapeutics, Inc. position as of Q2 2021 after selling out during the quarter.
  • Alpha DNA Investment Management sold 80 Global Blood Therapeutics, Inc. shares in Q2 2021, an estimated $3K.
  • Alpha DNA Investment Management first reported a position in Global Blood Therapeutics, Inc. in Q4 2020 and held it in 2 quarters.
  • Alpha DNA Investment Management's Global Blood Therapeutics, Inc. position peaked at $3K in Q1 2021.
  • 191 funds tracked by Wall St. Rank held Global Blood Therapeutics, Inc. as of Q2 2021.

Based on Alpha DNA Investment Management's 13F filing for Q2 2021, filed 10 Aug 2021.